Jasper Therapeutics, Inc. (JSPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jasper Therapeutics, Inc. on August 21, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Redwood City, California. Its common stock (JSPR) and redeemable warrants (JSPRW) are listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it references the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2026, which indicated that stockholders' equity fell below the minimum requirement of $2,500,000 mandated by Nasdaq Listing Rule 5550(b)(1).
Material Changes and Listing Status
On August 21, 2026, the Company received a notice from Nasdaq stating it no longer satisfies the minimum stockholders' equity requirement for continued listing. This notice has no immediate effect on the trading of the Company's securities. The Company has 45 calendar days (until October 5, 2026) to submit a plan to regain compliance.
Outlook, Management Commentary, and Risks
- Compliance Plan: The Company intends to submit a Compliance Plan to Nasdaq by October 5, 2026. If accepted, it may receive an extension of up to 180 days to regain compliance.
- Proposed Solution: Management anticipates regaining compliance through stockholder approval of the conversion of outstanding Non-Voting Convertible Preferred Stock at a special meeting. No assurances are provided that this approval will be obtained.
- Delisting Risk: If the Compliance Plan is rejected or the Company fails to regain compliance within the extension period, the Company may request a hearing before Nasdaq's Hearing Panel. There is no assurance that the Panel will grant continued listing or that the Company will maintain its listing on Nasdaq.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the ability to regain compliance and the outcome of regulatory processes, which are subject to risks and uncertainties.
Key Facts for Investor Verification
- Verify the exact stockholders' equity balance reported in the Form 10-Q for the period ended June 30, 2026.
- Monitor the date and outcome of the special stockholder meeting regarding the conversion of Non-Voting Convertible Preferred Stock.
- Track the submission and acceptance status of the Company's Compliance Plan with Nasdaq by October 5, 2026.
- Review the Company's liquidity position and cash runway to assess its ability to fund operations while addressing the equity deficiency.